Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou(Brigham and Women's Hospital), F. Stephen Hodi(Harvard University), Matthias Piesche(Catholic University of the Maule), Fengmin Zhao(Dana-Farber Cancer Institute), Kathleen M. Mahoney(Beth Israel Deaconess Medical Center), Scott J. Rodig(Brigham and Women's Hospital), Michael P. Manos(Harvard University), Anita Giobbie‐Hurder(Institute for Tourism), Gordon J. Freeman(Dana-Farber Cancer Institute), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Lauren M. Eastman(Dana-Farber Cancer Institute), Jingjing Li(Peking University), Lisa H. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinqi Wu(Dana-Farber Brigham Cancer Center), Glenn Dranoff(Dana-Farber Cancer Institute)
Cited by 363
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k